1.

Synthesis and Characterization of Intermediates, Known and
Unknown analogs
General procedure S1 for the synthesis of 2-cyanoacetamides 15d, 15e and 15g
2-Cyanoacetic acid (510 mg, 6.00 mmol, 1.00 eq.) was dissolved in DCM (15 mL). A catalytic amount of DMF (0.03 mL) was added at 0 o C, following by oxalyl chloride (0.51 mL, 6.00 mmol, 1.00 eq.). The reaction mixture was stirred at 0 o C for another 5 minutes and then at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to about 8 mL, diluted with 10 mL DCM, and added to another flask containing the corresponding amine (6.00 mmol, 1.00 eq.) and triethylamine (1.67 mL, 12.0 mmol, 2.00 eq.) in DCM (30 mL) at 0 o C. The mixture was stirred at 0 o C for 5 minutes and then at room temperature for 3 hours. The solvent was removed in vacuo and the crude residue was purified by column chromatography over silica gel with hexane and ethyl acetate.
2-Cyano-N-ethylacetamide (15d)
1 General procedure S1 was followed using ethylamine THF solution (2 M, 3.00 mL) to afford the product as a white solid, (350 mg, 3.12 mmol, 52%). Mp: 73-74 o C (Lit. 
N-butyl-2-cyanoacetamide (15e)
2 General procedure S1 was followed using n-butylamine (0.50 mL) to afford the product as a white solid (413 mg, 2.95 mmol, 49% Methyl 2-amino-5-ethylthiophene-3-carboxylate (13c) 5 General procedure S2 was followed using n-butyraldehyde 16a (0.45 mL, 5.00 mmol)
and methyl 2-cyanoacetate 15b (0.44 mL, 5.00 mmol) to afford the product as an orange solid (751 mg, 4.05 mmol, 76% 
Butyl 2-amino-5-ethylthiophene-3-carboxylate (13d)
General procedure S2 was followed using n-butyraldehyde 16a (0.45 mL, 5.00 mmol) and butyl 2-cyanoacetate 15c (0.71 mL, 5.00 mmol) to afford the product as a colourless liquid (605 mg, 2.66 mmol, 53% 
2-Amino-N-butyl-5-ethylthiophene-3-carboxamide (13f)
General procedure S2 was followed using n-butyraldehyde 16a (1. 
2-Amino-5-ethylthiophene-3-carboxamide (13g)
General procedure S2 was followed using n-butyraldehyde 16a (0.45 mL, 5.00 mmol) and 2-cyanoacetamide 15f (420 mg, 5.00 mmol) to afford the product as an off white solid (410 mg, 2.41 mmol, 48% 
2-Amino-5-ethyl-N-(2-hydroxyethyl)thiophene-3-carboxamide (13h)
General procedure S2 was followed using n-butyraldehyde 16a (1.17 mL), 2-cyano- For the synthesis of furancarboxyl amide-containing intermediates 22q, 24a, 24b, or the known analogs 18b, 22a-d, 22f, 22g, 22k, 22p and 25a general procedure provided in the paper was used.
General Procedure for the synthesis of furancarboxyl amides 12a-k, 18a-b and
22a-q
The furoic acid chlorides 14a and 14b were prepared in situ: thionyl chloride (1.10 eq.) was added dropwise to a mixture of 5-nitrofuran-2-carboxylic acid or 2-furoic acid (1.10 eq.), triethylamine (1.50 eq.) in DCM (0.4 M) under a N 2 atmosphere. The reaction mixture was stirred at room temperature for 5 hours. Then crude 14a or 14b was added to another flask containing the corresponding amine or aniline (1.00 eq.) and triethylamine (2.00 eq.) in DCM (0.4 M). The reaction mixture was stirred at room temperature for 5 hours. The solvent was then removed under reduced pressure and the crude reaction mixture was purified by column chromatography
Ethyl 5-butyl-2-(5-nitrofuran-2-carboxamido)thiophene-3-carboxylate (12b): The general procedure was followed using 2-amiothiophene 13b (454 mg, 2.00 mmol).
The crude reaction mixture was purified by column chromatography on silica gel 
Methyl 5-ethyl-2-(5-nitrofuran-2-carboxamido)thiophene-3-carboxylate (12c):
The general procedure was followed using 2-amiothiophene 13c (370 mg, 2.00 mmol). The crude reaction mixture was purified by column chromatography on silica gel 
Butyl 5-ethyl-2-(5-nitrofuran-2-carboxamido)thiophene-3-carboxylate (12d):
The general procedure was followed using 2-amiothiophene 13d (454 mg, 2.00 mmol).
The crude reaction mixture was purified by column chromatography on silica gel (7:1, hexane/ethyl acetate) to afford the product as an orange solid (425 mg, 1.16 mmol, 58% 
N-(5-ethyl-3-(ethylcarbamoyl)thiophen-2-yl)-5-nitrofuran-2-carboxamide (12e):
The general procedure was followed using 2-amiothiophene 13e (60 mg, 0.30 mmol).
The crude reaction mixture was purified by column chromatography on silica gel (2:1, hexane/ethyl acetate) to afford the product as a yellow solid (57 mg, 0.16 mmol, 57% 
N-(3-(butylcarbamoyl)-5-ethylthiophen-2-yl)-5-nitrofuran-2-carboxamide (12f):
The general procedure was followed using 2-amiothiophene 13f (120 mg, 0.53 mmol). The crude reaction mixture was purified by column chromatography on silica gel (4:1, hexane/ethyl acetate) to afford the product as a yellow solid (114 mg, 0.31 mmol, 59% 
N-(5-ethyl-3-(2-hydroxyethylcarbamoyl)thiophen-2-yl)-5-nitrofuran-2-
carboxamide (12h): The general procedure was followed using 2-amiothiophene 13h 376.0579; found 376.0576.
5-Ethyl-2-(5-nitrofuran-2-carboxamido)thiophene-3-carboxylic acid (12i):
The general procedure was followed using thiophen-2-amine 13i (600 mg, 3.50 mmol).
The crude reaction mixture was purified by column chromatography on silica gel (1:2, S13 hexane/ethyl acetate) to afford the product as a yellow solid (267 mg, 0.86 mmol, 25% 
5-nitro-N-(thiophen-2-yl)furan-2-carboxamide (12j):
The general procedure was followed using thiophen-2-amine 13j (400 mg, 4.03 mmol). The crude reaction mixture was purified by column chromatography on silica gel 
S15
The general procedure in the paper was followed using aniline (0.219 mL, 2.40 mmol). The crude reaction mixture was purified by column chromatography on silica gel 
General procedure S3 Synthesis of analogues 20a-c and 21
A solution of the carboxylic acid (1.00 eq) in thionyl chloride was stirred under reflux (~80 °C) for 3-6 h under an inert atmosphere and then concentrated under reduced pressure. Triethylamine (3.00 eq) was added to a solution of 13g (0.95 eq) in anhydrous DCM. The freshly prepared acid chloride was dissolved in anhydrous DCM and added dropwise to the solution of 13g. The resulting reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure to afford the crude title compounds which were purified as detailed below.
5-Ethyl-2-(2-nitrobenzamido) thiophene-3-carboxamide (20a)
General procedure S3 was followed using 2-nitrobenzoic acid (334 mg, 2.0 mmol, 1.00 eq) and 13g (323 mg, 1.9 mmol, 0.95 eq). The crude reaction mixture was purified by column chromatography on silica gel ( 
5-Ethyl-2-(3-nitrobenzamido) thiophene-3-carboxamide (20b)
General procedure S3 was followed using 3-nitrobenzoic acid (334 mg, 2.0 mmol, 1.00 eq) and 13g (323 mg, 1.9 mmol, 0.95 eq). The crude reaction mixture was purified by column chromatography on silica gel (from 2:1 to 3:2, hexane/ethyl acetate) and the product was recrystallized from EtOAc to afford the product as a yellow solid (84 mg, 0.3 mmol, 14% 
5-Ethyl-2-(4-nitrobenzamido) thiophene-3-carboxamide (20c)
General procedure S3 was followed using 4-nitrobenzoic acid (334 mg, 2.0 mmol, 1.00 eq) and 13g (323 mg, 1.9 mmol, 0.95 eq). The crude reaction mixture was purified by column chromatography on silica gel (3:2, hexane/ethyl acetate) and the product was recrystallized in EtOAc to afford the product as a dark red solid (68 mg, S17 
N-(3-carbamoyl-5-ethylthiophen-2-yl)-4-nitro-1H-pyrazole-3-carboxamide (21)
General procedure S3 was followed using 4-nitro-1H-pyrazole-3-carboxylic acid (314 mg, 2.0 mmol, 1.00 eq) and 13g (323 mg, 1.9 mmol, 0.95 eq). The crude reaction mixture was purified by column chromatography on silica gel (ethyl acetate)
to afford the product as a yellow solid (232 mg, 0.8 mmol, 42% 
N-cyclohexyl-5-nitrofuran-2-carboxamide (22a)
The general procedure in the paper was followed using cyclohexylamine (283 mg, 8 The general procedure in the paper was followed using aniline (186 mg, 2.00 mmol).
mmol
5-Nitro-N-phenylfuran-2-carboxamide (22b)
N-benzyl-5-nitrofuran-2-carboxamide (22c) 10
The general procedure in the paper was followed using 1-phenylmethanamine (409 mg, 2.85 mmol). The crude reaction mixture was purified by column chromatography on silica gel (3:1, hexane/ethyl acetate) to afford the product as a white crystalline 
5-Nitro-N-(pyridin-2-ylmethyl)furan-2-carboxamide (22d) 9
The general procedure in the paper was followed using pyridin-2-ylmethanamine (308 mg, 2.85 mmol). The crude reaction mixture was purified by column chromatography on silica gel 8 The general procedure in the paper was followed using 3-bromoaniline (544 µL, 5.00 mmol). The crude reaction mixture was purified by column chromatography on silica gel 8 The general procedure in the paper was followed using 3-methoxyaniline (615 mg, 5.00 mmol). The crude reaction mixture was purified by column chromatography on silica gel (2:1, hexane/ethyl acetate) to afford the product as a yellow solid (587 mg, The general procedure in the paper was followed using 4-methoxyaniline (615 mg, 5.00 mmol). The crude reaction mixture was purified by column chromatography on silica gel (2:1, hexane/ethyl acetate) to afford the product a yellow solid (670 mg, 2.56 mmol, 51% 
N-(3-bromophenyl)-5-nitrofuran-2-carboxamide (22f)
N-(3-methoxyphenyl)-5-nitrofuran-2-carboxamide (22g)
mmol, 45%
)
N-(3-methoxy-5-(trifluoromethyl)phenyl)-5-nitrofuran-2-carboxamide (22m):
The general procedure was followed using 3-methoxy-5-(trifluoromethyl)aniline (335 mg, 2.00 mmol). The crude reaction mixture was purified by column chromatography on silica gel (3:1, hexane/ethyl acetate) to afford the product as a yellow solid (335 mg, 1.01 mmol, 51% 
N-(3,5-bis(trifluoromethyl)phenyl)-5-nitrofuran-2-carboxamide (22n):
The general procedure was followed using 3-5-bis(trifluoromethyl)aniline (653 mg, 2.85 mmol, 0.95 eq). The crude reaction mixture was purified by column chromatography on silica gel (2:1, hexane/ethyl acetate) to afford the product as an off white crystalline solid after recrystallization (715 mg, 1.9 mmol, 68 % 
N-(4-hydroxy-3-(trifluoromethyl)phenyl)-5-nitrofuran-2-carboxamide (22r):
Pyridine (0.16 mL, 2.00 mmol, 10.0 eq.) was added dropwise to a 2M solution of HCl in Et 2 O (1.00 mL, 1.00 mmol, 10.0 eq.), the pyridine salt precipitated immediately and the reaction mixture was stirred at room temperature for 10 minutes. The solvent was removed under reduced pressure and transferred to a 10 mL microwave tube. 22o
(33 mg, 0.10 mmol) was added and the mixture was irradiated by microwave at 160 0 C for 5 minutes. After cooling, ethyl acetate (20 mL) was added and the reaction mixture was washed with water (2×8 mL). 
S24
The general procedure in the paper was followed using 4-amino-phenol (959 mg, 8.00 mmol). The crude reaction mixture was purified by column chromatography on silica gel 
N-(4-hydroxy-3-methylphenyl)-5-nitrofuran-2-carboxamide (22q)
The general procedure in the paper was followed using 4-amino- 
General procedure S4 synthesis of imines 24a and 24b
5-nitro-2-furaldehyde 23 (1 eq) in DCM was added dropwise to a stirring solution of amine (1 eq) in DCM. The resulting solution was stirred overnight at room temperature and then concentrated under reduced pressure to afford the crude title compounds.
N-((5-nitrofuran-2-yl)methylene) aniline (24a)
11
S29
HPLC analysis was performed using a Gilson UV-VIS 155 HPLC system under the gradient conditions shown in the analysis method below (Table 3) (RP, reverse phase), XTerra RP 18 5 µm column (3.0 x 50 mm, Waters). The concentration of the compounds were ca. 4 mM, injection volumes were 20 µL, flow rate was 1 mL/min and detection was acquired using UV spectroscopy (254 nm) observed that the majority of the analogs were soluble at concentrations of above 10 µM in aqueous solution containing 1% DMSO. Considering most of our analogs are 10-1000 fold more potent than nifurtimox (5), the concentrations that need to be achieved may ultimately be considerably lower than is the case for nifurtimox (5) and hence we suspect that the solubility of our analogs may be acceptable. This can only be addressed, of course, through more advanced studies that fall outside the scope of this report.
Calculated Chemical and Drug-likeness Properties
Excitingly, approximately 50% of the analogs were predicted to have medium to good blood-brain barrier penetration with logBBB values > 0 (Table S6 , column 5). 12g
and 22s, the most active analogs against T. brucei in vitro, both have relatively good calculated logBBB values of 0.0755 and 0.5033 respectively, which are considerably better than nifurtimox (5) . The majority of the analogs were predicted not to be substrates of the p-glycoprotein (P-gp) efflux pump (column 6). Potential affinity for P 450 proteins was widely predicted to exist (as exemplified for the D26 isozyme in Table S6 , column 7). However, there is still chemical space to explore for the development of novel analogs that are not predicted to bind P 450 s as the potent trypanocidal analogs 22b and 22c with EC 50 values around 28 nM and 27 nM respectively against T. brucei were predicted to have low affinity for this class of metabolizing enzymes.
